



BN/SB/08A/B

Substitute Form 1469 TO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

**Complete If Known**

Application Number	10/565,161
Filing Date	November 30, 2005
First Named Inventor	Pnina FISHMAN
Confirmation No.	7305
Examiner Name	Not Yet Known
Attorney Docket Number	FISHMAN=19A

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
M-C-H	AA	US-2004/0167094 A1	08-26-2004	FISHMAN et al.	
	AB	US-2004/0137477 A1	07-15-2004	FISHMAN et al.	
	AC	US-2005/0074451	04-07-2005	YEDNOCK et al.	
	AD	US-2005/0065192	03-24-2005	YEDNOCK et al.	
M-C-H	AE	US-2002/0119924	08-29-2002	BENDELE et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>4</sup> Number <sup>5</sup> Kind Code <sup>6</sup> (if known)				
M-C-H	AF	AU 200051825 A1	10-26-2000	FELDMANN et al.		

Examiner  
SignatureDate  
Considered

1/20/08

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/565,161
		Filing Date	November 30, 2005
		First Named Inventor	Pnina FISHMAN
		Group Art Unit	7305
		Examiner Name	Not Yet Known
Sheet 2	of 3	Attorney Docket Number	FISHMAN=19A

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS); title of article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s); volume-issue number(s); publisher, city and/or country where published	T <sup>2</sup>
McC-H	AG	FISHMAN et al., <i>Evidence for Involvement of Wnt Signaling Pathway in IB-MECA Mediated Suppression of Melanoma Cells</i> ; <u>Oncogene</u> , Vol. 21, pp.4060-4064 (2002)	
	AH	FISHMAN et al., <i>Targeting the A3 Adenosine Receptor for Cancer Therapy: Inhibition of Prostate Carcinoma Cell Growth by A3AR Agonist</i> ; <u>Anticancer Research</u> Vol. 23: pp. 2077-2083 (2003)	
	AI	MADI et al., <i>A3 Adenosine Receptor Activation in Melanoma Cells, Association Between Receptor Fate and Tumor Growth Inhibition</i> ; <u>The Journal of Biological Chemistry</u> , Vol. 278, No. 43, pp.42121-42130, October 24, 2003	
	AJ	OHANA et al., <i>Inhibition of Primary Colon Carcinoma Growth and Liver Metastasis by the A3 Adenosine Receptor Agonist CF101</i> ; <u>British Journal of Cancer</u> , Vol. 89, pp. 1552-1558 (2003) XP-002332046	
	AK	FISHMAN et al., <i>An Agonist to the A3 Adenosine Receptor Inhibits Colon Carcinoma Growth in Mice Via Modulation of GSK-3<math>\beta</math> and NF-<math>\kappa</math>B</i> ; <u>Oncogene</u> Vol. 23, pp.2465-2471 (2004)	
	AL	SZABO et al., <i>Suppression of Macrophage Inflammatory Protein (MIP)-1<math>\alpha</math> Production and Collagen-Induced Arthritis by Adenosine Receptor Agonists</i> ; <u>British Journal of Pharmacology</u> , Vol. 125, pp. 379-387 (1998)	
	AM	MABLEY et al., <i>The Adenosine A3 Receptor Agonist, N6-(3-Iodobenzyl)-Adenosine-5'-N-Methyluronamide, is Protective in Two Murine Models of Colitis</i> ; <u>European Journal of Pharmacology</u> , Vol. 466, pp. 323-329, 2003	
	AN	BAHARAV et al., <i>Antiinflammatory Effect of A3 Adenosine Receptor Agonists in Murine Autoimmune Arthritis Models</i> ; <u>Journal of Rheumatology</u> , Vol. 32; No. 3, pp. 469-76, 2005	
	AO	MONTESINTOS et al., <i>Adenosine A2A or A3 Receptors are Required for Inhibition of Inflammation by Methotrexate and Its Analog MX-68</i> ; <u>Arthritis &amp; Rheumatism</u> , Vol. 48, No.1, pp.240-247, January 2003.	
	AP	MADI et al., <i>The A3 Adenosine Receptor is Highly Expressed in Tumor Versus Normal Cells: Potential Target for Tumor Growth Inhibition</i> ; <u>Clinical Cancer Research</u> , Vol. 10, pp. 4472-4479, July 1, 2004	
	AQ	GESSI et al., <i>Elevated Expression of A3 Adenosine Receptors in Human Colorectal Cancer is Reflected in Peripheral Blood Cells</i> ; <u>Clinical Cancer Research</u> , Vol.10, 5895-5901, September 1, 2004	
Mc-IT	AR	CHAN et al., <i>Molecular Action of Methotrexate in Inflammatory Diseases</i> ; <u>Arthritis Research</u> , Vol. 4, No. 4; 4, pp. 266-273, 2002.	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

(use as many sheets as necessary)

Sheet	2
-------	---

2

C

3

**Complete if Known**

Application Number

10/565,161

Filing Date

November 30, 2005

First Named Inventor

**Pnina FISHMAN**

**Group Art Unit**

7305

**Examiner Name**

Not Yet Known

Attorney Docket Number

FISHMAN=19A

[illegible]

Examiner  
Signature

Date  
Considered

1/20/08

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.